NEW YORK, Jan. 16, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community.Today we are offering reports on A, IQV, PKI, and TMO which can be accessed for free by signing up to www.wallstequities.com/registration. This morning, WallStEquities.com tracks the recent performance of Agilent Technologies Inc. (NYSE: A), IQVIA
Santa Clara, California headquartered Agilent Technologies Inc.'s shares finished Friday's session 1.31% higher at $71.73. A total volume of 1.45 million shares was traded. The stock has gained 6.96% in the last month, 6.20% over the previous three months, and 47.84% over the past year. The Company's shares are trading above their 50-day and 200-day moving averages by 5.24% and 14.95%, respectively. Moreover, shares of Agilent Technologies, which provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide, have a Relative Strength Index (RSI) of 68.60. Get the full research report on A for free by clicking below at:
Shares in Durham, North Carolina headquartered IQVIA Holdings Inc. ended the day 0.18% higher at 100.04 with a total trading volume of 742,045 shares. The stock has advanced 1.62% in the previous three months and 29.60% over the past year. The Company's shares are trading 7.56% above their 200-day moving average. Moreover, shares of IQVIA Holdings, which provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and Asia/Pacific, have an RSI of 50.49. Gain free access to the research report on IQV at:
Waltham, Massachusetts headquartered PerkinElmer Inc.'s stock rose 1.64%, closing the session at $78.89. A total volume of 436,295 shares was traded. The Company's shares have gained 10.93% in the last month, 9.86% in the previous three months, and 48.96% over the past year. The stock is trading 8.36% above its 50-day moving average and 17.34% above its 200-day moving average. Additionally, shares of PerkinElmer, which provides products, services, and solutions to the diagnostics, research, environmental, industrial, food, and laboratory services markets worldwide, have an RSI of 76.15.
On December 19th, 2017, research firm Bank of America/ Merrill upgraded the Company's stock rating from 'Underperform' to 'Neutral'. Register for your free report coverage on PKI at:
Thermo Fisher Scientific
On Friday, shares in Waltham, Massachusetts headquartered Thermo Fisher Scientific Inc. finished the session 0.72% higher at $210.17. A total volume of 1.49 million shares was traded. The stock has gained 10.91% in the last month, 8.68% over the previous three months, and 43.98% over the past year. The Company's shares are trading above their 50-day and 200-day moving averages by 9.15% and 16.32%, respectively. Moreover, shares of the Company, which provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide, have an RSI of 80.29.
On January 05th, 2018, research firm BTIG Research initiated a 'Buy' rating on the Company's stock. Get the free research report on TMO at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: firstname.lastname@example.org Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/medical-laboratories-and-research-stocks-research-reports-released-on-agilent-technologies-iqvia-holdings-perkinelmer-and-thermo-fisher-scientific-300583020.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Some drugs or therapeutic agents cause undesirable reactions in lungs, known as drug-induced ...
Sleep disorders are collectively known as ''Somnipathy.'' There are over 70 different medically ...View All